Large cohort study links short leukocyte telomere length with higher cataract risk and worse lens opacity, highlighting biological aging in vision loss.

The Unknown Journey of the Final Fantasy VII Remake trilogy continues on Switch 2, as preorders for Final Fantasy VII Rebirth are now live. The middle chapter in the trilogy heads to the Nintendo ...

Prophylactic treatment for hemophilia B necessitates lifelong, regular intravenous factor IX infusions. Gene therapy offers the possibility of a single-dose treatment that produces durable endogenous ...

The fall semester at the University of Delaware is nearing its end. But first, final exams, which begin on Dec. 11. UD’s Academic Coaching and Tutoring (ACT) offers a variety of resources that help ...

Pokémon Go’s final event of the season, "Final Justice," is themed around fighting-type Pokémon and it runs from Nov. 25-30. As part of this event, you can get up to two free Raid Passes per day by ...

Ethan Krieger (He/Him) is an editor at DualShockers that got started in the writing industry by covering professional basketball for a sports network. Despite being a diehard sports fan (mainly ...

Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...

Final Audience is a Wish in Hollow Knight: Silksong from the Second Sentinel, an autonomous warrior tasked with protecting the now fallen Citadel. This Wish is put on the Songclave wish wall after the ...

Final Fantasy is a massive series, even if you’re only looking at the mainline games. A lot of entries have some kind of feature that is more on the experimental side, and that can help or hurt the ...

Callum is a seasoned gaming managing editor for a number of publications and a gamer who will always try to shine a spotlight on indie games before giving AAA titles the time of day. He loves nothing ...

Amgen's bemarituzumab trial has taken a turn, with a final analysis showing weaker survival benefits than previously found in an earlier pre-specified interim analysis. In June, Amgen and China ...